Review Article

Emerging trends in RNA-based therapeutics: From messenger RNA vaccines to RNA interference

Manisha Sharma

Department of Pharmacy, SBS College of Pharmacy, Amritsar, Punjab, India

Correspondence:
Dr. Manisha Sharma, Department of Pharmacy, SBS College of Pharmacy, Amritsar, Punjab, India.
E-mail : drmanish.pun@gmail.com

How to cite this article:
Sharma M. Emerging trends in RNA-based therapeutics: From messenger RNA vaccines to RNA interference. Innov Pharm Planet 2023;11(2):18-22.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 17-04-2023
Date of Revision: 20-04-2023
Date of Acceptance: 12-05-2023

ABSTRACT

Efficient RNA delivery to target cells remains a major challenge in RNA therapeutics. Current methods, such as lipid nanoparticles and viral vectors, face issues such as immunogenicity, limited tissue specificity, and toxicity. Researchers are working on safer, more precise delivery systems to overcome these hurdles. Off-target effects are another concern, particularly in gene silencing and editing therapies, where unintended genes may be affected. Efforts are underway to improve RNA sequence accuracy and delivery methods to minimize these risks. Regulatory and manufacturing challenges also impede progress, as large-scale production and standardization of RNA molecules are complex. Future directions focus on developing stable, efficient delivery systems, improving RNA design, and enhancing targeting mechanisms. The integration of RNA therapeutics with personalized medicine and gene editing may unlock new treatments for previously untreatable diseases. As research progresses, RNA-based therapies are expected to become key tools in treating various conditions, from cancer to genetic and infectious diseases.

Keywords: Gene silencing, messenger RNA vaccines, RNA aptamers, RNA delivery systems, RNA interference, RNA-based therapeutics

Introduction

RNA-based therapeutics has emerged as a transformative approach in modern medicine, leveraging the unique properties of RNA to target a wide array of diseases. This overview will explore the historical development, significance, and future potential of RNA as a therapeutic agent.[1]

The journey of RNA-based therapeutics began with the discovery of antisense oligonucleotides (ASOs) in the early 1980s, which inhibited protein synthesis.[2] This foundational work laid the groundwork for subsequent innovations, including the advent of RNA interference (RNAi) in the late 1990s, which further catalyzed research and funding in this field. By the 2000s, the introduction of small interfering RNAs (siRNAs) marked a significant milestone, allowing for targeted gene silencing and expanding the therapeutic landscape beyond traditional small-molecule drugs and antibodies.[3]

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275
DOI: 10.31690/ipplanet.2023.v011i02.006	

RNA's potential as a therapeutic agent is underscored by its ability to interact with a broader range of biological targets than conventional drugs. Unlike protein-targeted therapies, which have limited access to the human genome (only about 0.05% is currently drugged), RNA can theoretically target any gene by selecting the appropriate nucleotide sequence. This flexibility is crucial, especially given that a significant portion of the human genome is transcribed into noncoding RNAs, presenting new avenues for therapeutic intervention.

The purpose of this review is to summarize the current advancements in RNA-based therapeutics, including messenger RNA (mRNA) vaccines, RNAi, and other RNA modalities such as ribozymes and aptamers. The review will also address the mechanisms of action, applications in various disease contexts, and the challenges faced in the development and delivery of these therapies. Recent breakthroughs, particularly the approval of the first mRNA vaccine in 2020, have highlighted the rapid progress in this field and the potential for RNA-based therapies to address previously "undruggable" targets.

As research continues, the integration of innovative delivery systems and chemical modifications will be crucial for enhancing the efficacy and safety of RNA therapeutics.[4]

Mechanism of RNA Therapeutics

RNA-based therapeutics utilizes the unique properties of various RNA molecules to modulate gene expression and provide novel treatment options for a range of diseases. Understanding the mechanisms underlying these therapies is crucial for their development and application.

Basics of RNA biology

RNA plays several critical roles in cellular processes, primarily as a mRNA, a regulator (micro RNA [miRNA]), and a mediator of gene silencing (siRNA).

Messenger RNA

Serves as a template for protein synthesis, carrying genetic information from DNA to ribosomes, where proteins are produced.

Small interfering RNA

These are short, double-stranded RNA (dsRNA) molecules that induce RNAi, a process that silences specific mRNA targets to prevent the translation of harmful proteins.

MicroRNA

These are small, non-coding RNA molecules that regulate gene expression by binding to complementary mRNA sequences, leading to mRNA degradation or inhibition of translation.[5]

RNA translation and gene regulation

The process of RNA translation involves converting the information encoded in mRNA into functional proteins. This process is tightly regulated by various factors, including ribosomes, transfer RNA, and regulatory RNAs like miRNAs.

Gene regulation by RNA occurs through several mechanisms

Translational control

miRNAs can bind to target mRNAs, leading to their degradation or inhibition of translation, thereby regulating protein levels in the cell.

RNA interference

siRNAs are incorporated into the RNA-induced silencing complex (RISC), which then binds to complementary mRNA and facilitates its degradation, effectively silencing the gene from which it was transcribed.

Mechanisms underlying RNA therapeutics

RNA therapeutics operates through distinct mechanisms depending on the type of RNA involved:

Messenger RNA therapeutics

These involve the introduction of synthetic mRNA into cells to produce therapeutic proteins. This approach has been notably successful in the development of mRNA vaccines, which instruct cells to produce antigens that elicit an immune response against pathogens.

RNA interference

siRNA therapies target specific mRNAs for degradation, effectively silencing genes associated with diseases such as cancer and viral infections. This targeted approach allows for the modulation of gene expression without altering the underlying DNA.

Antisense oligonucleotides

These are short, single-stranded RNA molecules designed to bind to specific mRNA sequences, blocking their translation or modifying splicing patterns. ASOs can be tailored to target a wide range of genetic disorders, providing a versatile therapeutic strategy.

Ribozymes and aptamers

Ribozymes are catalytic RNA molecules that can cleave specific RNA targets, while aptamers are RNA sequences that bind to specific proteins or other molecules, inhibiting their function. Both offer additional avenues for therapeutic intervention.

Overall, the versatility of RNA-based therapeutics allows for innovative approaches to treating diseases that were previously considered "undruggable." As research progresses, enhancing the delivery and stability of these RNA molecules remains a critical focus to maximize their therapeutic potential.

Messenger RNA Vaccines: A Breakthrough in RNA Therapeutics

Development of messenger RNA Vaccines

mRNA vaccines represent a groundbreaking advancement in vaccine technology, particularly highlighted by their rapid development in response to the COVID-19 pandemic. The historical development of mRNA vaccines began with early research in the 1990s, which demonstrated the feasibility of using mRNA to induce immune responses. Initial successes included the use of liposome-encapsulated mRNA to elicit cytotoxic T-cell responses against viral antigens. However, significant advancements in mRNA stability, delivery methods, and immunogenicity were necessary before these vaccines could be widely applied.[6]

The COVID-19 pandemic catalyzed the accelerated development of mRNA vaccines, particularly the Pfizer-BioNTech and Moderna vaccines. These vaccines were designed and produced in a matter of weeks, showcasing the flexibility and rapid adaptability of mRNA technology to emerging infectious diseases. Key technologies such as lipid nanoparticles (LNPs) were developed to enhance the stability and delivery of mRNA, allowing for effective cellular uptake and prolonged expression of the encoded antigens. In addition, self-amplifying RNA platforms were introduced, which incorporate

RNA-dependent RNA polymerase to enable the replication of the mRNA within cells, leading to increased antigen production and a more robust immune response.

Mechanism of action

The mechanism of action of mRNA vaccines involves the introduction of synthetic mRNA encoding specific antigen proteins into host cells. Once inside the cells, the mRNA is translated by the ribosomes into proteins that mimic the target pathogen's antigens. This process triggers an immune response, as the immune system recognizes these proteins as foreign, leading to the activation of both humoral and cellular immunity.

On vaccination, the immune system generates specific antibodies and activates T cells that can recognize and eliminate infected cells. This dual response is crucial for establishing long-term immunity and memory against future infections by the actual pathogen.[7]

Clinical applications

The success of mRNA COVID-19 vaccines has opened the door for exploring their potential in other infectious diseases and cancer immunotherapy. Clinical trials have demonstrated that mRNA vaccines can elicit strong immune responses against various pathogens, including influenza and Zika virus. Furthermore, ongoing research is investigating the use of mRNA technology for cancer treatment, where mRNA vaccines can be designed to express tumor-specific antigens, potentially leading to targeted immune responses against cancer cells. Early trials have shown promising results, including antigen-specific T-cell responses and improved disease-free survival in patients.[8]

Challenges and limitations

Despite their potential, mRNA vaccines face several challenges and limitations. One significant issue is the stability of mRNA molecules, which are prone to degradation by nucleases in the body. This challenge is often addressed through the use of lipid nanoparticles, which protect the mRNA and facilitate its delivery to target cells.

Delivery remains a critical hurdle, as effective cellular uptake is necessary for the vaccines to elicit a strong immune response. In addition, the immune response to mRNA vaccines can vary among individuals, with some experiencing more robust reactions than others. Understanding these variations and optimizing the formulation and delivery of mRNA vaccines will be essential for maximizing their efficacy and safety in broader applications.[9]

RNA Interference and Gene Silencing

Overview of RNAi technology

RNAi is a natural cellular mechanism that regulates gene expression through the degradation of specific mRNA molecules. This process is initiated by dsRNA, which can be introduced into cells either exogenously or produced endogenously. The key components of RNAi include siRNA, short hairpin RNA (shRNA), and miRNA, each playing distinct roles in gene silencing.

siRNAs are typically 20–25 nucleotides long and are processed from longer dsRNA by the enzyme Dicer. Once formed, siRNAs are incorporated into the RISC, where they guide the complex to complementary mRNA targets, leading to their degradation. Similarly, shRNAs are expressed from DNA vectors and processed into siRNAs within the cell. miRNAs, on the other hand, are derived from endogenous transcripts and primarily function by binding to the 3' untranslated regions of target mRNAs, inhibiting their translation.[10]

Gene silencing and therapeutic potential

The gene-silencing capability of RNAi has significant therapeutic potential, particularly in diseases where aberrant gene expression plays a critical role. By selectively targeting and silencing these genes, RNAi can be used to downregulate the expression of proteins involved in cancer, genetic disorders, and viral infections. This specificity allows for a more targeted approach compared to traditional therapies, which may affect multiple pathways and lead to unwanted side effects.

Applications in disease

RNAi technology has shown promise in various clinical applications:

Cancer treatment

RNAi can target oncogenes or genes involved in tumor progression, offering a novel approach to cancer therapy. Preclinical studies have demonstrated the ability of siRNAs to inhibit tumor growth in various cancer models.

Genetic disorders

RNAi has the potential to address genetic disorders caused by mutations in specific genes. By silencing the expression of mutant alleles, RNAi can mitigate the effects of the disorder, as seen in conditions like Huntington's disease and certain forms of muscular dystrophy.

Viral infections

RNAi can also be employed to target viral RNA, thereby inhibiting viral replication. This approach has been explored for infections such as HIV, hepatitis, and influenza, where siRNAs can be designed to target viral genes specifically.

Therapeutic RNAi in clinical trials

Several RNAi-based drugs have progressed to clinical trials, with some receiving regulatory approval. For instance, Parisian (Onpattro) is an FDA-approved siRNA therapy for hereditary transthyretin amyloidosis, demonstrating the feasibility of RNAi in treating systemic diseases. In addition, Givlaari (givosiran) is another approved RNAi therapy targeting acute hepatic porphyria. Ongoing research continues to explore new RNAi therapeutics for a range of diseases, with numerous candidates currently in various stages of clinical trials.[11]

Challenges in RNAi therapeutics

Despite the promise of RNAi, several challenges remain

Off-target effects

RNAi can unintentionally silence non-target genes, leading to potential side effects. This necessitates the careful design of siRNAs to minimize off-target interactions.

Delivery systems

Efficient delivery of RNAi therapeutics to target tissues is a significant hurdle. Current strategies often rely on lipid nanoparticles or viral vectors, but these methods can be limited by tissue specificity and potential immunogenicity.

Immune responses

The introduction of synthetic RNA molecules can provoke immune responses, which may diminish the therapeutic efficacy and lead to adverse effects. Ongoing research is focused on optimizing RNAi constructs to reduce immunogenicity while maintaining efficacy.[12]

Other Emerging RNA-based Therapies

Long non-coding RNAs

Long non-coding RNAs (lncRNAs) are a significant class of non-coding RNAs that are defined by their length, typically exceeding 200 nucleotides. They play diverse roles in cellular processes, including gene regulation, chromatin remodeling, and cellular signaling. lncRNAs are increasingly recognized for their potential therapeutic applications, particularly in cancer and other diseases where their expression patterns are often altered.

lncRNAs can function as molecular scaffolds, guiding protein complexes to specific genomic locations, or as decoys, sequestering miRNAs or transcription factors to modulate gene expression. Their tissue-specific expression profiles make them attractive targets for therapeutic interventions. For instance, certain lncRNAs are overexpressed in specific cancer types, suggesting that targeting these lncRNAs could inhibit tumor growth or progression. Research is ongoing to develop strategies that utilize ASOs or siRNAs to specifically downregulate oncogenic lncRNAs, thereby offering a novel approach to cancer therapy.[13]

RNA aptamers

RNA aptamers are short, single-stranded RNA molecules that can bind to specific target proteins with high affinity and specificity. This property makes them valuable tools for targeted therapy, as they can be designed to inhibit or modulate the activity of proteins involved in disease processes.

The use of RNA aptamers in therapy includes applications in cancer treatment, where they can be used to target tumor-associated antigens or signaling molecules, potentially blocking pathways that promote tumor growth. In addition, RNA aptamers can serve as delivery vehicles for therapeutic agents, guiding drugs directly to disease sites while minimizing off-target effects. Their ability to be engineered for specific targets enhances their therapeutic potential, making them a promising area of research in RNA-based therapeutics.

CRISPR-Cas and RNA-guided gene editing

The CRISPR-Cas system has revolutionized gene editing by utilizing RNA molecules as guides to direct the Cas9 nuclease to specific genomic locations. This RNA-guided approach allows for precise modifications of the DNA sequence, enabling targeted gene disruption, insertion, or replacement.[14]

In therapeutic contexts, CRISPR-Cas technology has significant implications for precision gene editing, particularly in genetic disorders where specific mutations can be corrected. The ability to design guide RNAs that target disease-causing mutations opens new avenues for treating conditions such as sickle cell disease and cystic fibrosis. Furthermore, ongoing research aims to enhance the specificity and efficiency of RNA-guided gene editing, addressing challenges such as off-target effects and delivery methods.

Challenges and Future Directions

Key challenges

Despite the significant progress made in RNA-based therapeutics, several key challenges remain that need to be addressed to fully realize their potential:

Stability and degradation of RNA molecules

RNA molecules are inherently unstable and prone to degradation by ubiquitous enzymes called ribonucleases (RNases). This instability can limit the efficacy of RNA therapeutics, as the RNA may degrade before reaching its intended target. Strategies to enhance RNA stability, such as chemical modifications and the use of delivery vehicles, are crucial to improving their therapeutic potential.

Immune responses and safety concerns

The introduction of exogenous RNA molecules can trigger immune responses, leading to potential safety issues. RNA can be recognized by pattern recognition receptors, such as Toll-like receptors, which can activate the innate immune system and cause unwanted side effects. Careful design of RNA sequences and formulations is necessary to minimize immunogenicity while maintaining therapeutic efficacy.

Efficient delivery systems

Effective delivery of RNA therapeutics to target tissues and cells is a significant challenge. RNA molecules are large, negatively charged molecules that cannot easily cross cell membranes. Developing safe and efficient delivery systems, such as lipid nanoparticles, polymers, and conjugates, is essential for ensuring that the RNA reaches its intended site of action.

Future research areas

As the field of RNA therapeutics continues to evolve, several promising research areas have emerged that could further expand their therapeutic potential:

Expanding therapeutic applications

While RNA-based therapies have shown promise in treating various diseases, including cancer, genetic disorders, and viral infections, there is still room for expansion into new therapeutic areas. Ongoing research is exploring the use of RNA therapeutics for neurodegenerative diseases, autoimmune disorders, and cardiovascular diseases, among others.

Improving RNA stability and delivery mechanisms

Continued research into enhancing RNA stability and developing more efficient delivery systems is crucial for improving the efficacy and safety of RNA therapeutics. This includes exploring new chemical modifications, novel delivery vehicles, and targeted delivery approaches to specific cell types or tissues.[15]

Reducing costs and scalability for widespread use

For RNA-based therapies to have a significant impact on global health, they need to be affordable and scalable for widespread use. Ongoing research is focused on developing cost-effective manufacturing processes and improving the scalability of RNA production to make these therapies more accessible to patients worldwide.

In conclusion, while RNA-based therapeutics has made significant strides in recent years, with several approved drugs and many more in clinical trials, there is still work to be done to fully harness their potential. By addressing key challenges related to stability, delivery, and safety, and expanding their therapeutic applications, RNA-based therapies hold great promise for transforming the treatment of a wide range of diseases in the future.

Conclusion

RNA-based therapeutics has advanced significantly, offering innovative solutions for treating a range of diseases through technologies such as mRNA vaccines and RNAi. Despite progress, challenges in RNA stability, delivery, and specificity persist. Addressing these issues and improving RNA technologies will be key to unlocking their full potential. As research continues, RNA-based therapies are set to become integral tools in modern medicine, providing new avenues for previously untreatable conditions.

References

1. Halloy F, Biscans A, Bujold KE, Debacker A, Hill AC, Lacroix A, *et al*. Innovative developments and emerging technologies in RNA therapeutics. RNA Biol 2022;19:313-32.
2. Zhou LY, Qin Z, Zhu YH, He ZY, Xu T. Current RNA-based therapeutics in clinical trials. Curr Gene Ther 2019;19:172-196.
3. Burnett JC, Rossi JJ. RNA-based therapeutics: Current progress and future prospects. Chem Biol 2022;19:60-71.
4. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004;4:1285-1294.
5. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet 2022;23:265-80.
6. Nitika, Wei J, Hui AM. The development of mRNA vaccines for infectious diseases: recent updates. Infect Drug Resist 2021;14:5271-85.
7. Naik R, Peden K. Regulatory considerations on the development of mRNA vaccines. In: mRNA Vaccines. Cham: Springer International Publishing; 2020. p. 187-205.
8. De Ferrari GM, Schwartz PJ. Vagus nerve stimulation: From pre-clinical to clinical application: Challenges and future directions. Heart Failure Rev 2011;16:195-203.
9. Burnett JC, and Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012;19:60-71.
10. Banerjee S, Banerjee A, Gill SS, Gupta OP, Dahuja A, Jain PK, *et al*. RNA interference: A novel source of resistance to combat plant parasitic nematodes. Front Plant Sci 2017;8:834.
11. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009;1:142-51.
12. Haussecker D. Current issues of RNAi therapeutics delivery and development. J Control Release 2014;195:49-54.
13. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol 2013;10:925-33.
14. Upadhyay SK, Kumar J, Alok A, Tuli R. RNA-guided genome editing for target gene mutations in wheat. G3 Genes Genomes Genet 2013;3:2233-8.
15. Tse HN, Borrow R, Arkwright PD. Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy. Expert Rev Vaccines 2020;19:1115-27.